Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-66P (RNA, U4 small nuclear 66, pseudogene) is a **pseudogene** of the U4 small nuclear RNA (snRNA) family[1]. U4 snRNA is a component of the spliceosome, a large ribonucleoprotein complex essential for pre-mRNA splicing, but pseudogenes like RNU4-66P do **not** encode functional RNA and are generally considered non-functional remnants in the genome derived from the functional U4 snRNA genes[1]. There is no evidence or published data indicating that RNU4-66P is transcribed, produces functional RNA, or is involved in any therapeutic mechanism, disease association, or drug interactions[1]. The naming convention, linking "pseudogene" directly to "66" in the abbreviation, confirms this is not a protein, enzyme, receptor, transporter, transcription factor, or any classical drug target. RNU4-66P should not be considered a therapeutic target; it is annotated as a **pseudogene**, meaning there is no evidence for any canonical biological function or clinical relevance[1]. If the intent was to find a functional member of the U4 snRNA family (such as RNU4-2, which is disease-associated and biologically active[3][4][5]), this entry is **incorrect** for the purposes of drug targeting, therapy, or molecular function discovery. **Additional notes:** - **Pseudogenes** are not regarded as drug targets unless there is very specific evidence of biological activity, which does not exist for RNU4-66P. - The presence of "pseudogene" in the name, continued lack of function annotation, and the absence of any listing in disease roles or drug association databases confirms that this is not a relevant target for therapeutic, biomarker, or drug development purposes[1]. **Summary of structured information:** - The provided entry "RNU4-66P" is a pseudogene, not a functional molecule or receptor. - The entry is **incorrect** if the intent was a therapeutically actionable target, chromatin modifier, signaling molecule, or transcript relevant in disease. If information about a functional U4 small nuclear RNA molecule is needed, consider reviewing "RNA, U4 small nuclear 2 (RNU4-2)", which is implicated in spliceosome function and neurodevelopmental disorders[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 66, pseudogene (RNU4-66P).